ECCO 2024

Are all JAKies the same?

The quest for predictive markers goes on...

S1P-Modulators from a safety perspective

Real-world data from a H2H-study on Vedolizumab vs. Tofacitinib in UC

Primary sclerosing cholangitis – lessons from a large PSC-IBD registry

Finally here: controlled trials in surgery!

Cell-based therapies: The end of the story or the bright future?

Treatment targets in 2024 - a silent revolution

A spotlight on the PROFILE study

Combination of different drug classes - risks and benefits

Mirikizumab in CD

IL-23 in UC

Ustekinumab first, anti-p19 second?

Next chapter in S1P- and JAK-inhibition

Obefazimod & IL23R-CAR-Tregs - new molecules in focus

Mirikizumab vs Ustekinumab

Changing the PROFILE of how we treat CD

Mirikizumab in crohn's disease

VIVID 1: Mirikizumab in Crohn's Disease

Darvadstrocel for complex perianal fistulas and Crohn’s Disease

VIVID 1: Comparison of mirikizumab with ustekinumab in Crohn’s disease

Tregs - a treatment for the future?

Results of the phase II PIZZICATO (ritlecitinib & brepocitinib) in Crohn's disease

Mirikizumab in moderate to severe Crohn’s disease: overall assessment of the VIVID-1 trial

PIZZICATO - new JAKies for crohn's disease

PIZZICATO - neue JAKs für Morbus Crohn

Resultaten van de fase 2 PIZZICATO (ritlecitinib & brepocitinib) studie in ziekte van Crohn

Mirikizumab στη θεραπεία της μέτριας προς βαρειά NC: Συνολική ανάλυση μελέτης Vivid-1

Mirikizumab vs Ustekinumab

VIVID 1- Comparação do Mirikizumab com o Ustecinumab na Doença de Crohn

Mirikizumab bei Morbus Crohn

VTX-002 in patients with moderate to severe UC

VTX002 (S1P-modulator) & obefazimod in ulcerative colitis

Risankizumab & guselkumab in ulcerative colitis

The efficacy of biologics and small molecules in microscopic colitis – an ECCO Confer Cases study results

Mirikizumab in anti-TNF failures with UC

Long term outcome of Obefazimod in UC

VTX002 (S1P-Modulator) & Obefazimod bei Colitis Ulcerosa

VTX-002 in pazienti con colite ulcerosa da moderata a grave

Risankizumab & Guselkumab bei Colitis Ulcerosa

lange-termijns uitkomst van obefazimod in UC

Leki biologiczne i małocząsteczkowe w terapii mikroskopowych zapaleń jelit – wnioski z badania ECCO Confer Cases

Therapy in transition

Still a long road ahead in standards of care in IBD – the results of an E-QUALITY survey

Comparability examination between SB17 and Ustekimumab originator

Marzenia a rzeczywistość – wyniki ankiety E-QUALITY na temat standardów opieki w IBD

Therapie im Umbruch

Esame di comparabilità tra SP17 e ustekimumab originator

Changing treatment paradigm in CD

PROFILE: practice-changing results

Results from the PROFILE-trial

Should we proactively treat CD-patients having small bowel lesions on capsules?

Early intervention in Crohn´s disease therapy

Allogenic mesenchymal stem cells for complex fistula in CD: End of the story?

Biomarker for biological loss of response in CD?

PROFILE: Biomarkers not successfull for therapy prediction

Cambiano i paradigmi di trattamento nelle malattie di crohn

Intervenção terapêutica precoce na doença de Crohn

Injection de cellules souches mesenchimateuses allogéniques dans les fistules complexes de la maladie de Crohn: Fin de l'histoire?

Faut-il traiter les patients avec les lesions de Crohn en videocapsules?

PROFILE: Biomarker nicht erfolgreich zur Prädiktion der Therapieantwort

Biomarker for biological loss of response in CD?

Risultati dallo studio PROFILE

Guselkumab & Golimumab have complementary effects when given together

Towards the proactive management of AS-UC responding to IB-steroids

Vers un traitement plus agressif de la colite aigüe grave cortico-sensible

Guselkumab & Golimumab ont des effets complémentaires lorqu'ils sont associés

Therapy in transition

Use of CAR-Tregs in IBD: preclinical data

Immunohomeostasis by regulatory CAR-T cells!?

Personalized treatment in IBD: reality or hype?

HD-WLE with segmental reinspection is not inferior to HD-dye-based CE in detecting colorectal neoplasia in IBD

Utilizzo di cellule CAR Tregs nelle MICI: dati preclinici

Therapie im Umbruch

gepersonaliseerde aanpak van IBD: realiteit of hype?

Immunohomöstase durch regulatorische CAR-T-Zellen!?

HD-WLE με επανεξέταση των τμημάτων δεν υπολείπεται της χρωμοενδοσκόπησης στην ανίχνευση νεοπλασίας στο παχύ έντερο στις ΙΦΝΕ

Colectomy and the natural history of PSC – lessons form a large PSC-IBD registry

Implication of proctocolectomy in patients affected by UC

Extended mesenterectomy is not superior to mesenteric sparing resection to prevent postoperative recurrence of CD

End of the Kono-S legend!

No changes to surgical techniques for ileosecal disection in CD

MIRACLE project: Avoidance of protective Ileostomy

Randomised clinical trials finally coming to IBD surgery!

MIRACLE-Projekt: Verzicht auf protektive Ileostomie

La fin de la legende du Kono-S!

Los ensayos clínicos aleatorizados llegan a la cirugía de las EII

Implicazioni della proctocolectomia in pazienti affetti da colite ulcerosa

Kolektomia a historia naturalna PSC – czy istnieje zależność?

Η εκτεταμένη εκτομή του μεσεντερίου δεν υπερέχει της διατήρησής του για την πρόληψη της μετεγχειρητικής νόσου του Crohn

Molecular healing, our next goal?

Cicatrización molecular: nuestro próximo objetivo?

Molecular effects of IL-23p19 blockade

Transcriptomic profiles in patients with UC receiving filgotinib

Análise do Transcriptoma em doentes com colite ulcerosa tratados com Filgotinib

Molekulare Effekte der IL-23p19-Blockade

Diet & Lifestyle: Keys for the management of IBD!

Diet & Lifestyle: Keys for the management of IBD!